Revolution Medicines reported that daraxonrasib met overall survival and progression-free survival endpoints in a Phase 3 trial in metastatic pancreatic ductal adenocarcinoma, with results prompting the company to end the study early. Patients receiving daraxonrasib lived a median of 13.2 months versus 6.7 months with standard chemotherapy. Revolution also flagged an FDA national priority voucher status, which could accelerate review after submission. Analysts and investors will now focus on which subset effects drove benefit and how regulators interpret efficacy in a disease area with limited treatment options and historically poor survival.